Cargando…

Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models

BACKGROUND: Despite the poor prognosis of triple-negative breast cancer (TNBC) brain metastases, there are no approved systemic therapies. We explored the DNA-damaging poly(ADP-ribose) polymerase inhibitor (PARPi) niraparib in intracranial mouse models of breast cancer susceptibility protein (BRCA)-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sambade, Maria J, Van Swearingen, Amanda E D, McClure, Marni B, Deal, Allison M, Santos, Charlene, Sun, Kaiming, Wang, Jing, Mikule, Keith, Anders, Carey K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212882/ https://www.ncbi.nlm.nih.gov/pubmed/32642648 http://dx.doi.org/10.1093/noajnl/vdz005

Ejemplares similares

BSCI-06 COMPREHENSIVE ANALYSIS OF THE IMMUNOGENOMICS OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES FROM LCCC1419
por: Van Swearingen, Amanda, et al.
Publicado: (2022)

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
por: Sun, Kaiming, et al.
Publicado: (2018)

Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419
por: Routh, Eric D., et al.
Publicado: (2022)

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
por: Wang, Zebin, et al.
Publicado: (2019)

Rationale and Design for the LOnger-term effects of SARS-CoV-2 INfection on blood Vessels And blood pRessure (LOCHINVAR): an observational phenotyping study
por: Lip, Stefanie, et al.
Publicado: (2022)

2066 Functional characterization of mutant BRCA1
por: Barrows, John, et al.
Publicado: (2018)

First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics
por: Friedland, Barbara A., et al.
Publicado: (2016)

Intracranially injectable multi-siRNA nanomedicine for the inhibition of glioma stem cells
por: Manju, Cheripelil Abraham, et al.
Publicado: (2021)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
por: Maiorano, Mauro Francesco Pio, et al.
Publicado: (2023)

Driver mutations in USP8 wild-type Cushing’s disease
por: Sbiera, Silviu, et al.
Publicado: (2019)

Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
por: Wei, Qiang, et al.
Publicado: (2022)

Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment
por: Portet, Sylvain, et al.
Publicado: (2019)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival
por: Gittleman, Haley, et al.
Publicado: (2019)

Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy
por: Belcaid, Zineb, et al.
Publicado: (2020)

Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts
por: Póti, Ádám, et al.
Publicado: (2018)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Rare central nervous system tumors in adults: a population-based study of ependymomas, pilocytic astrocytomas, medulloblastomas, and intracranial germ cell tumors
por: Ho, Vincent K Y, et al.
Publicado: (2022)

Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas
por: Rossmeisl, John H, et al.
Publicado: (2020)

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
por: Spring, Laura M., et al.
Publicado: (2022)

Successful Treatment of a Patient With Brain Metastasis From Ovarian Cancer With BRCA Wild Type Using Niraparib: A Case Report and Review of the Literature
por: Zhang, Zhenhua, et al.
Publicado: (2022)

THER-06. GENOMIC AND IMMUNE CHARACTERIZATION OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES
por: Vincent, Benjamin, et al.
Publicado: (2019)

Niraparib for ovarian cancer
Publicado: (2021)

2342 Protein production as an early pharmacodynamics biomarker for RNA-targeting therapies
por: Self, Wade K., et al.
Publicado: (2018)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma
por: Ding, Jie, et al.
Publicado: (2022)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
por: Lohse, I, et al.
Publicado: (2015)

Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma
por: Wang, Zihao, et al.
Publicado: (2023)

GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data
por: Ajaib, Shoaib, et al.
Publicado: (2023)

Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
por: Spring, Laura M., et al.
Publicado: (2022)

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
por: Yap, Timothy A, et al.
Publicado: (2022)

BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells
por: Fan, S, et al.
Publicado: (2006)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma
por: Jones, Lindsey E, et al.
Publicado: (2020)

Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects
por: Mirza, Mansoor Raza, et al.
Publicado: (2022)

Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks
por: Li, Kay Ka-Wai, et al.
Publicado: (2019)

Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures
por: Verheul, Cassandra, et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_oc2ri321vk4kl1bimmdikgbnfr